Business Context and Reporting Period
This Form 8-K was filed by Greatbatch, Inc. on June 15, 2007, reporting the completion of a previously announced acquisition. The filing details the purchase of Enpath Medical, Inc., a Minnesota corporation, which became a wholly-owned, indirect subsidiary of Greatbatch following the transaction.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margin, debt, or liquidity metrics for Greatbatch, Inc. The primary financial data point disclosed is the transaction consideration:
- Acquisition Price: $14.38 per share in cash for outstanding Enpath shares not tendered in the prior offer.
- Transaction Structure: Cash tender offer followed by a merger.
Material Changes
The material change reported is the completion of the acquisition of Enpath Medical, Inc. on June 15, 2007. This transaction was executed pursuant to an Agreement and Plan of Merger dated April 28, 2007. The merger involved Greatbatch Ltd. (Parent) and Chestnut Acquisition Corporation (Purchaser), with Enpath surviving as the subsidiary.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors related to the acquisition. It references a press release (Exhibit 99.1) dated June 18, 2007, for further details on the announcement.
Investor Verification Checklist
- Verify the total number of Enpath shares acquired to calculate the total transaction value.
- Review the attached Press Release (Exhibit 99.1) for strategic rationale and integration plans.
- Confirm the impact of the acquisition on Greatbatch's balance sheet and pro forma financials in subsequent filings (e.g., 10-Q or 10-K).
- Check for any dissenters' rights exercised by Enpath shareholders that may affect the final cash outlay.